In Vitro Antiviral Screening for Henipaviruses at BSL4

Bruce A Mungall

doi:10.1007/978-1-0716-3283-3_7

In Vitro Antiviral Screening for Henipaviruses at BSL4

Methods Mol Biol. 2023:2682:93-102. doi: 10.1007/978-1-0716-3283-3_7.

Author

Bruce A Mungall^{1

2

3}

Affiliations

¹ Australian Animal Health Laboratory, CSIRO Livestock Industries, Geelong, VIC, Australia.
² GlaxoSmithKline Vaccines, Seoul, South Korea.
³ Vaccines and Immune Therapies, Astra Zeneca, Singapore, Singapore.

PMID: 37610576
DOI: 10.1007/978-1-0716-3283-3_7

Abstract

In vitro screening for antivirals is an essential step in the development of effective treatments against new and emerging pathogens. Here, we describe a simple, cell-based screening assay for evaluating antiviral effectiveness against Hendra and Nipah live virus infection under BSL4 conditions.

Keywords: Antiviral screen; Hendra virus; Immunolabeling; In vitro; Nipah virus.

MeSH terms

Antiviral Agents / pharmacology
Henipavirus*
Research Design

Substances

Antiviral Agents